News & Events
Peplin Announces Executive Management Appointments
18 / 08 / 2008
Peplin, Inc. (ASX:PLI) announced today that Tom Wiggans has been appointed Chief Executive Officer effective immediately. Mr Wiggans is currently Chairman of Peplin's board of directors and will also continue in that role. Prior to joining Peplin, Tom Wiggans served as…
Peplin secures approximately US$24m in additional financing
18 / 08 / 2008
Peplin, Inc. (ASX:PLI) today announced the successful arrangement of a private placement of common stock and warrants to raise approximately US$24.0 million (Placement). The financing will primarily fund Phase III of clinical development of PEP005 (ingenol mebutate) for actinic (solar)…
Additional information lodged with FDA for US clinical trial
13 / 08 / 2008
Sunshine Heart, Inc. (ASX: SHC) has today lodged additional information with the US Food and Drug Administration (FDA) in support of the Company's Investigational Device Exemption (IDE) application for approval to undertake a US clinical trial of Sunshine Heart's innovative C-PulseTM heart…
Sales contracts worth $2.3 million signed since 1 July 2008
12 / 08 / 2008
Highlights: $1.2 million contract signed for Phase III schizophrenia study In total, nine sales contracts signed since 1 July 2008, worth $2.3 million $3 million in revenue already locked in for FY 2009 CogState Ltd (ASX:CGS) today announced…
Australian company Xenome presents Xen2174 data on relief of pain in cancer patients at international conference
01 / 08 / 2008
A new drug for the treatment of severe pain under development by Australian biotechnology company Xenome Limited ("Xenome") has shown promise for the relief of chronic pain in cancer patients in a Phase II clinical trial. Relief of pain in cancer patients continues to…
KaloBios Initiates Phase 1/2 Trial of HumaneeredT Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Mechanically Ventilated Patients
19 / 05 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced the initiation of a Phase 1/2 clinical trial of KB001, a HumaneeredT, high-affinity antibody fragment that KaloBios is developing for the treatment of Pseudomonas aeruginosa infections. …
Uptake Medical Announces Successful Completion of Patient Enrollment in Pilot Safety & Feasibility Clinical Trial for Patients with Heterogeneous Emphysema
16 / 05 / 2008
Uptake Medical announced today that it has completed patient enrolment in a phase I safety and feasibility clinical trial for the company's proprietary minimally invasive Bronchoscopic Thermal Vapor AblationT (BTVAT) treatment for patients suffering from heterogeneous emphysema with upper…
Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of its Renessar Treatment for Incontinence in Women
15 / 05 / 2008
Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that it has secured $49.5 million in Series D preferred stock financing. The round was led by Versant Ventures, with ThreeArch Partners and Skyline Ventures also participating as new investors. The…
Underwritten rights issue to raise $5.4 million
05 / 05 / 2008
Sunshine Heart, Inc. (ASX: SHC) today announced the terms of an underwritten non-renounceable rights issue to raise $5.4 million. Under the rights issue, eligible shareholders will be invited to subscribe for 4 new shares for every 11 shares held at the record date at an offer price of 7…
KaloBios Expands Senior Management Team -- Adds Project Management and Additional Business Development Expertise --
05 / 05 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced two additions to its senior management team that significantly strengthen the company's project management and pharmaceutical business development expertise. Jeanne Y. Jew, previously Vice…
KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003 -- First HumaneeredT Anti-GM-CSF Monoclonal Antibody Part of Comprehensive Inflammation Development Program --
28 / 04 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced that the company has completed dosing subjects in a U.S. Phase 1 clinical trial of its third drug candidate, KB003. The study is a placebo-controlled, single-dose, dose-escalation Phase 1 trial in…
Portland Orthopaedics Share Purchase Plan closes
15 / 04 / 2008
Portland Orthopaedics Limited (ASX: PLD) closed its Share Purchase Plan ("SPP") on 9 April. The SPP raised $280k. A total of 3.7 million new shares will be allotted tomorrow. "We were pleased with the response to the SPP by our shareholders given market conditions and we…
ChemGenex Reports Oral Bioavailability of Omacetaxine and Expands on Mechanism of Action
15 / 04 / 2008
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today that pre-clinical data characterizing the bioavailability and mechanism of action of omacetaxine mepesuccinate (formerly known as Ceflatoninr) were presented on Monday local time at the American Association of…
C-Pulse abstract presented at ISHLT Meeting, Boston
08 / 04 / 2008
Sunshine Heart, Inc. (ASX:SHC) announced today that a presentation at 28th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT) will highlight results from the first human trial of the Company's C-PulseT System, an implantable, non-blood contacting heart…
New Therapies Fight Phantom Noises of Tinnitus
01 / 04 / 2008
Modern life is loud. The jolting buzz of an alarm clock awakens the ears to a daily din of trucks idling, sirens blaring, televisions droning, computers pinging and phones ringing - not to mention refrigerators humming and air-conditioners thrumming. But for the 12 million Americans who…
ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients with the T315I Mutation at International Leukemia Conference
01 / 04 / 2008
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) has announced interim results from its ongoing phase 2/3 trial of omacetaxine mepesuccinate (formerly known as Ceflatoninr) in chronic myeloid leukemia (CML) patients with the T315I mutation. The data continue to show an increase in the…
KaloBios Initiates Phase 1/2 Trial of HumaneeredT Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Cystic Fibrosis Patients
31 / 03 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced the initiation of a Phase 1/2 clinical trial of KB001, a HumaneeredT, high-affinity antibody fragment that KaloBios is developing for the treatment of P. aeruginosa infections. The trial is being…
ChemGenex Launches Multi-Site Omacetaxine Clinical Trial in AML Patients
11 / 03 / 2008
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today that it has launched a new phase 2 study evaluating the use of omacetaxine mepesuccinate (formerly homoharringtonine, HHT) in refractory or relapsed acute myeloid leukemia (AML) patients who have failed intensive…
KaloBios Initiates Phase 1/2 Trial of KB002 Engineered Monoclonal Antibody in Persistent Asthma
10 / 03 / 2008
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced the initiation of a Phase 1/2 clinical study of KB002, the company's anti-GM-CSF monoclonal antibody, as a potential treatment for persistent asthma. The blinded, placebo-controlled…
PHARMAXIS' FIRST STEPS INTO CHINA
07 / 03 / 2008
Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced that a clinical trial application for Bronchitol to treat bronchiectasis has been accepted for evaluation by China's State Food and Drug Administration (SFDA). All pharmaceutical companies are required to undertake a study in a…
Portland adopts innovative financing with NAB
27 / 02 / 2008
Portland Orthopaedics Limited (ASX:PLD) has finalised an innovative $1.25 million financing package with The National Australia Bank (nab). The cornerstone of the financing is an innovative asset leasing package whereby Portland's surgical instrument sets will qualify as a…
Portland Orthopaedics appoints Australian distributor
26 / 02 / 2008
Portland Orthopaedics (ASX:PLD) has engaged Taylor Bryant Surgical Specialties Division of Lifehealthcare Pty Ltd to market and sell Portland's hip replacement products throughout Australia. The three-year agreement is effective immediately. Lifehealthcare is exclusive…